慢性髓性白血病患者骨髓微环境的特征揭示CXCL14可作为新的治疗选择
该研究对初诊慢性髓性白血病(CML)患者的骨髓微环境进行分子与功能表征,发现患者骨髓细胞微环境中CXCL14表达缺失;恢复CXCL14可抑制CML白血病起始干细胞(LSC)维持、增强伊马替尼体外反应,并在患者来源异种移植NSG-SGM3小鼠中显著抑制CML植入,抑制程度甚至大于伊马替尼。
要点
- CML患者骨髓间充质干细胞对正常及CML骨髓CD34+CD38-细胞的支持能力增强。
- CML患者骨髓细胞微环境中CXCL14表达缺失,恢复CXCL14可抑制CML LSC维持并增强伊马替尼体外反应。
- CXCL14在患者来源异种移植NSG-SGM3小鼠中抑制CML植入的程度甚至大于伊马替尼。
核心结论
- 研究发现CXCL14对CML LSC生长具有抑制作用,CXCL14可能成为靶向CML LSC的治疗选择。
研究设计与样本
- 研究对初诊CML患者的骨髓微环境进行分子与功能表征,采用长期培养起始细胞实验、RNA测序及体外与NSG-SGM3小鼠体内实验。
主要发现
- 长期培养起始细胞实验显示,CML患者骨髓间充质干细胞对正常和CML骨髓CD34+CD38-细胞的支持能力增强。
- RNA测序检测到CML患者骨髓细胞微环境中细胞因子和生长因子表达失调,其中CXCL14在骨髓细胞微环境中缺失,而健康骨髓中表达。
- 恢复CXCL14在体外显著抑制CML LSC维持并增强其对伊马替尼的反应,在体内抑制NSG-SGM3小鼠的CML植入。
- CXCL14治疗在患者来源异种移植NSG-SGM3小鼠中显著抑制CML植入,抑制程度甚至大于伊马替尼,且在TKI反应欠佳的患者中该抑制作用持续存在。
- 机制上,CXCL14上调CML LSC中炎症细胞因子信号,下调mTOR信号和氧化磷酸化。
关键数值与推荐
- CXCL14在CML患者骨髓细胞微环境中缺失,而在健康骨髓中表达。
- 恢复CXCL14在体外显著抑制CML LSC维持并增强其对伊马替尼的反应。
- CXCL14在患者来源异种移植NSG-SGM3小鼠中抑制CML植入的程度甚至大于伊马替尼。
临床怎么用
- 作者认为CXCL14可能成为靶向CML LSC的治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although tyrosine kinase inhibitors (TKIs) are effective in treating chronic myeloid leukemia (CML), they often fail to eradicate the leukemia-initiating stem cells (LSCs), causing disease persistence and relapse. Evidence indicates that LSC persistence may be because of bone marrow (BM) niche protection; however, little is known about the underlying mechanisms. Herein, we molecularly and functionally characterize BM niches in patients with CML at diagnosis and reveal the altered niche composition and function in these patients. Long-term culture initiating cell assay showed that the mesenchymal stem cells from patients with CML displayed an enhanced supporting capacity for normal and CML BM CD34+CD38- cells. Molecularly, RNA sequencing detected dysregulated cytokine and growth factor expression in the BM cellular niches of patients with CML. Among them, CXCL14 was lost in the BM cellular niches in contrast to its expression in healthy BM. Restoring CXCL14 significantly inhibited CML LSC maintenance and enhanced their response to imatinib in vitro, and CML engraftment in vivo in NSG-SGM3 mice. Importantly, CXCL14 treatment dramatically inhibited CML engraftment in patient-derived xenografted NSG-SGM3 mice, even to a greater degree than imatinib, and this inhibition persisted in patients with suboptimal TKI response. Mechanistically, CXCL14 upregulated inflammatory cytokine signaling but downregulated mTOR signaling and oxidative phosphorylation in CML LSCs. Together, we have discovered a suppressive role of CXCL14 in CML LSC growth. CXCL14 might offer a treatment option targeting CML LSCs.
引用
- Dolinska M, Cai H, Månsson A, et al. Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option. Blood. 2023. PMID: 37018663. doi:10.1182/blood.2022016896
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。